Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JUNIOR STRENGTH ADVIL vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
FDA-labeled: Temporary relief of minor aches and pains (e.g., headache, toothache, menstrual cramps, muscle aches, backache),Fever reduction,Off-label: Osteoarthritis, rheumatoid arthritis (in higher doses),Off-label: Patent ductus arteriosus closure in neonates
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
2-4 hours (terminal); prolonged in hepatic impairment and elderly.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Hepatic metabolism primarily via CYP2C9; also involves glucuronidation; major metabolites are hydroxylated and carboxylated forms.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily renal (90% as glucuronide conjugates and 10% unchanged); <5% biliary/fecal.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
90-99% bound to albumin; concentration-dependent.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
0.1-0.2 L/kg (low, consistent with high protein binding).
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 85-95% (ibuprofen susp/liquid); 80-100% (tablets/capsules).
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
e GFR 30-60 m L/min: reduce dose by 50% or extend interval to q8-12h; e GFR <30 m L/min: avoid use.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: avoid use.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day (or 1200 mg/day) for children ≥6 months.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Start at lowest effective dose (200 mg q6-8h); maximum 1200 mg/day; monitor renal function and GI bleeding risk.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
No FDA boxed warning for JUNIOR STRENGTH ADVIL (ibuprofen). However, NSAIDs in general carry a boxed warning for cardiovascular thrombotic events and gastrointestinal bleeding.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Cardiovascular risk: Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke,Gastrointestinal risk: Increased risk of GI bleeding, ulceration, and perforation,Renal effects: May cause renal impairment, especially in patients with pre-existing renal disease,Hypersensitivity reactions: Anaphylaxis, bronchospasm,Fluid retention and edema,Avoid use with other NSAIDs or in late pregnancy (risk of premature closure of ductus arteriosus)
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to ibuprofen or any component of the formulation,Asthma, urticaria, or allergic-type reactions after aspirin or other NSAID use,Treatment of perioperative pain in coronary artery bypass graft (CABG) surgery,Use in children with chickenpox (due to increased risk of severe skin reactions)
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid alcohol: increases risk of GI bleeding. Limit caffeine as may increase side effects. Can be taken with food or milk to minimize GI irritation.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Avoid during third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal dysfunction. First and second trimester use only if clearly needed; limited human data suggest low risk of major malformations but increased risk of miscarriage and cardiac defects.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01). Not expected to cause adverse effects in infants with short-term use at recommended doses. Avoid in nursing mothers breastfeeding preterm or low-birth-weight infants.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No specific dose adjustment recommended in pregnancy. However, use lowest effective dose for shortest duration. In third trimester, avoid use unless benefit outweighs risk of fetal toxicity.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
For pediatric patients, weight-based dosing is critical; typical dose is 5-10 mg/kg/dose every 6-8 hours. Avoid use in children with dehydration, bleeding disorders, or aspirin allergy. May mask signs of infection. Not recommended for children under 6 months.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Give with food or milk to reduce stomach upset.,Do not exceed recommended dose; overdose can cause liver damage or gastrointestinal bleeding.,Do not use with other products containing ibuprofen or NSAIDs.,Shake suspension well before measuring dose using appropriate dosing device.,Stop use and consult doctor if symptoms worsen or new symptoms occur.,Keep out of reach of children; in case of overdose, contact Poison Control immediately.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JUNIOR STRENGTH ADVIL vs ACTIQ, answered by our medical review team.
JUNIOR STRENGTH ADVIL is a NSAID Analgesic that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JUNIOR STRENGTH ADVIL and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JUNIOR STRENGTH ADVIL is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JUNIOR STRENGTH ADVIL and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JUNIOR STRENGTH ADVIL is classified as Category C. Avoid during third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal dysfunction. First and second trimester use only if clearly nee. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.